Condition
Localized Cancer
Total Trials
5
Recruiting
2
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (4)
Trial Status
Recruiting2
Terminated1
Active Not Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05406713Phase 2Active Not Recruiting
Pembrolizumab in Muscle-invasive Bladder Cancer
NCT07262489Phase 2RecruitingPrimary
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
NCT05510895Phase 2Completed
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
NCT06583460Not ApplicableRecruiting
Systematic Intervention to Improve Sexual Dysfunction
NCT04221828Phase 2Terminated
Trial of NanoPac Focal Therapy for Prostate Cancer
Showing all 5 trials